Fatigue News and Research RSS Feed - Fatigue News and Research

Parents severely underestimate time children spend on digital devices

Parents severely underestimate time children spend on digital devices

According to the American Optometric Association (AOA), parents severely underestimate the time their children spend on digital devices. An AOA survey reports that 83 percent of children between the ages of 10 and 17 estimate they use an electronic device for three or more hours each day. [More]
NuAire's Laminar Airflow Workstations create bacteria-free, clean air environment

NuAire's Laminar Airflow Workstations create bacteria-free, clean air environment

NuAire's AireGard ES NU-201 Table Top and NU-301 Console Horizontal Laminar Airflow Hoods provide a HEPA filtered clean work area that is ideal for operations requiring a particle-free, bacteria-free, clean air environment. [More]

NuAire Biosafety Cabinets offer proper ergonomics and improve laboratory safety

NuAire LabGard ES and CellGard ES (Energy Saver) brand of Class II Biological Safety Cabinets offer the proper ergonomics, reduce energy, and improve laboratory safety. [More]
α1-adrenoceptor blockade improves nocturia and sleep quality

α1-adrenoceptor blockade improves nocturia and sleep quality

Treatment with an α1-adrenoceptor antagonist drug is associated with significant improvements in nocturia, sleep quality and lower urinary tract symptoms in women with voiding symptoms, study findings show. [More]
Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). [More]

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA. [More]
CGP partners with Leader Prospects to serve employees of Indian companies

CGP partners with Leader Prospects to serve employees of Indian companies

Chestnut Global Partners (www.chestnutglobalpartners.org), a provider of culturally-aware employee assistance and wellness programs to companies worldwide, today announced that it has partnered with Leader Prospects, an HR and work/life consulting company based in India, to form CGP India (CGPI). [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
Counselling and guidance techniques may not be appropriate for many African countries

Counselling and guidance techniques may not be appropriate for many African countries

Counselling and guidance techniques developed in the Western world may not be appropriate for many African countries, where cultural influences, government policies and the availability of resources can have significant implications for service delivery. [More]
Letrozole drug results in higher birth rates in women with PCOS

Letrozole drug results in higher birth rates in women with PCOS

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine researchers. [More]
FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok. [More]
Doctors offer new minimally invasive system to treat patients with narrowed, failing aortic heart

Doctors offer new minimally invasive system to treat patients with narrowed, failing aortic heart

Doctors at the Orlando Health Heart Institute are offering a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery. Orlando Health is the only hospital in Orlando currently offering the Medtronic CoreValve® System. [More]
Hypertension does not respond to therapy due to inadequate diagnosis

Hypertension does not respond to therapy due to inadequate diagnosis

High blood pressure—also known as hypertension—is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy. This is frequently due to inadequate diagnosis, as Franz Weber and Manfred Anlauf point out in the current issue of Deutsches Ärzteblatt International. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). [More]
Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. [More]